EGFR and lung carcinoma: Miyoshi et al. and Baglivo et al. reported that activated mutations for EGFR were found in large-cell NE lung cancer tissues, which helped lung adenocarcinoma cells acquire resistance to EGFR tyrosine kinase inhibitors (TKIs) and NED [100,101].